Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
08/2000
08/17/2000WO2000047238A1 Integration of transplanted neural progenitor cells into neural tissue of immature and mature dystrophic recipients
08/17/2000WO2000047237A1 Encapsulated cells containing an amplified expression vector as a drug delivery device
08/17/2000WO2000047236A1 Matrices for drug delivery and methods for making and using the same
08/17/2000WO2000047210A1 Use of 4-amino pyridine for treatment of peripheral neuropathies
08/17/2000WO2000047202A1 Felbamate derived compounds
08/17/2000WO2000047199A1 Use of a cyclohexenone long-chain alcohol for treating neurodegenerative diseases
08/17/2000WO2000047194A2 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
08/17/2000WO2000047189A1 Pharmaceutical effervescent formulation containing metamizol
08/17/2000WO2000047185A1 SPRAY CONTAINING UBIQUINONE Q¿n?
08/17/2000WO2000047149A1 Gels formed by the interaction of poly(aldehyde) with various substances
08/17/2000WO2000030675A3 Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
08/17/2000WO2000026199A3 Use of n-substituted (3,6-dihydro)-2h-1,2-oxazine derivatives as selective mglur1 antagonists
08/17/2000WO2000012076A9 Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
08/17/2000WO2000009109A3 Pipecolic acid derivatives for vision and memory disorders
08/17/2000DE19956568A1 Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens Method and medicament for the inhibition of expression of a given gene
08/17/2000DE19905880A1 Spray enthaltend Ubichinon Qn Spray containing ubiquinone Q n
08/17/2000CA2362592A1 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
08/17/2000CA2362575A1 Spray containing ubiquinone qn
08/17/2000CA2362400A1 Triazolo-pyridazine derivatives as ligands for gaba receptors
08/17/2000CA2362392A1 Heterocyclic derivatives as inhibitors of factor xa
08/17/2000CA2362390A1 Heteroaryl amidines, methylamidines and guanidines as protease inhibitors
08/17/2000CA2362389A1 Piperidine and piperazine derivatives as inhibitors of the abeta fibril formation
08/17/2000CA2362272A1 Spirocyclic ketones and their use as tachykinin antagonists
08/17/2000CA2361293A1 33 human secreted proteins
08/17/2000CA2361034A1 Proteins related to neuronal regeneration and uses thereof
08/17/2000CA2360258A1 Felbamate derived compounds
08/17/2000CA2360233A1 Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
08/17/2000CA2360164A1 5-ht1f agonists
08/17/2000CA2360123A1 Encapsulated cells containing an amplified expression vector as a drug delivery device
08/17/2000CA2359785A1 .beta.-secretase enzyme compositions and methods
08/17/2000CA2359660A1 16-hydroxyestratrienes as selective estrogens
08/16/2000EP1028137A2 Polymeric matrices and their uses in pharmaceutical compositions
08/16/2000EP1027893A2 Alginate containing medicament and implant for treating fibrosis
08/16/2000EP1027891A2 Neuropeptide y antagonists
08/16/2000EP1027890A2 Homer a new target of treating psychiatric disorders
08/16/2000EP1027887A2 Matrix controlled release device
08/16/2000EP1027603A2 Pharmaceutical grade ginkgo biloba
08/16/2000EP1027429A1 Jnk3 modulators and methods of use
08/16/2000EP1027363A2 Adenosine a1-receptor agonists
08/16/2000EP1027350A1 Aminomethyl-benzo a]quinolizidine derivatives, preparation and therapeutic applications for neurodegenrative diseases
08/16/2000EP1027347A2 3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them
08/16/2000EP1027339A1 Method and reagents for n-alkylating ureides
08/16/2000EP1027336A1 Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
08/16/2000EP1027335A1 Ortho-hydroxypyridinone derivatives as iron chelating and antioxidant agents
08/16/2000EP1027332A1 Novel lactam metalloprotease inhibitors
08/16/2000EP1027325A2 Lipophilic diesters of chelating agents
08/16/2000EP1027067A1 Use of substances having oxytocin activity for preparation of medicaments for the treatment of affective pain syndromes
08/16/2000EP1027064A1 Method for removing undesirable toxic alkaloids from plants or vegetable preparations
08/16/2000EP1027059A2 Enhancement of morphogen activity
08/16/2000EP1027046A1 Antagonists of gonadotropin releasing hormone
08/16/2000EP1027043A1 Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents
08/16/2000EP1027040A2 Methods for modulating macrophage proliferation using polyamine analogs
08/16/2000EP1027036A2 Taste masked formulations
08/16/2000EP1026950A1 Treatment of schizophrenia with ampakines and neuroleptics
08/16/2000EP0923379A4 Intravenous magnesium gluconate for treatment of conditions caused by excessive oxidative stress due to free radical distribution
08/16/2000EP0877612B1 Use of piperazine derivatives for the treatment of cognitive disorders
08/16/2000EP0805802B1 Substituted phenyl compounds as endothelin antagonists
08/16/2000EP0799045B1 Treatment of hyperexcited nerve cell functions
08/16/2000EP0584108B1 Pharmaceutical composition comprising ibuprofen salt
08/16/2000CN1263439A Nutritional composition for subjects under stress
08/16/2000CN1263095A New tricycloacylamide compound, its preparation method and medicinal composition containing them
08/16/2000CN1263087A Substituted alkyl tetramine derivative
08/16/2000CN1262945A Preparation method of medicine Huanshen Xingnao Dan for curing encephalomyelopathy
08/16/2000CN1262944A Preparation method of medicine Huaqi Huannao Dan for curing encephalomyelopathy
08/16/2000CN1055472C Oxazolo quinolyl-one derivatives, their preparation method and application and use as medicine
08/16/2000CN1055468C Alkylaminoindane compounds process for preparing them and pharmaceutical compositions containing them,and use
08/16/2000CN1055401C Chinese patent drug for curing epilepsy
08/15/2000US6103936 Reacting aldehyde, sulfide, sulfone, or sulfoxide with formamide in presence of acid catalyst, and optionally a dehydrating agent
08/15/2000US6103932 Useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, and neuropathological disorders
08/15/2000US6103925 Muscle contraction inhibitors; modulator with selectivity for charybdotoxin-sensitive, calcium-dependent potassium channels
08/15/2000US6103910 D-proline derivatives
08/15/2000US6103903 Anxiolytic agents, anticonvulsants, cognition activators
08/15/2000US6103877 Purified antibody which specifically binds to human hypermethylated in cancer-1 polypeptide of specific amino acid sequence or its immunoreactive fragments; for diagnosis/ prognosis of cell proliferative disorders such as cancer
08/15/2000US6103771 Method of treating neuroma pain
08/15/2000US6103766 Substituted or unsubstituted phenylsulfonamide-phenylamine derivatives useful for treating the disorders related to central nervous system
08/15/2000US6103759 Halogen substituted carbamate compounds from 2-phenyl-1, 2-ethanediol
08/15/2000US6103752 Therapeutic heterocyclic compounds
08/15/2000US6103737 Aryl- and arylamino- substituted heterocycles as corticotropin releasing hormone antagonists
08/15/2000US6103731 Imidazol[1,5-c]quinazolines; a new class of GABA brain receptor
08/15/2000US6103725 High affinity to the dopamine d4 receptor; antagonists; antipsychotic agents, e.g. schizophrenia, with reduced side-effects; antipsychotic agents; anxiolytic and antiemetic agents; motoric functions, addiction, sleep, feeding
08/15/2000US6103724 Exhibit mainly antipsychotic effects, e.g., schizophrenia, organic mental disorders, affective disorders, anxiety, personality disorders; neuroleptic activitiy; atypical antipsychotics, cognition activators, antidepressants;
08/15/2000US6103721 Heteroaryl-substituted pyridazino quinoline compounds
08/15/2000US6103720 Ketobenzamides as calpain inhibitors
08/15/2000US6103715 Compounds that bind to the dopamine d4 receptor and their use as anxiolytic agents, treatment for schizophrenia, and drug screening; side effect reductioon
08/15/2000US6103711 Inhibitors of interleukin-1β converting enzyme
08/15/2000US6103527 Nucleotide sequence from gene expressed in proliferating endothelial cells; for controlled gene expression especially for transgenic tissues and gene therapy
08/15/2000US6103513 Novel proteolytic enzyme; for the treatment of immune, proliferative and degratory defects
08/15/2000US6103507 Protein used to raise an immunological response against a bacteria; bactericides
08/15/2000US6103491 Methods and compositions for identifying morphogen analogs
08/15/2000US6103261 Opioid formulations having extended controlled release
08/15/2000US6103258 Administering a therapeutic dose of an opioid analgesic agonist and an amount of nalmefene to enhance the effects of dopamine-increasing opioid receptors and reduce the effects of dopamine-decreasing opioid receptors.
08/15/2000US6102254 Pharmaceutical compositions in semisolid form and a device for administration thereof
08/15/2000CA2136553C 7-(2-aminoethyl)-benzothiazolones
08/15/2000CA2105385C Treatment of cognitive disorders
08/10/2000WO2000046371A1 Tau-conotoxin peptides
08/10/2000WO2000046352A1 Human t cell effectors expressing cd86 molecule and therapeutic use thereof
08/10/2000WO2000046253A1 Process for the production of multiple cross-linked hyaluronic acid derivatives
08/10/2000WO2000046248A1 Use of agonists or antagonists of mip-3a in therapy
08/10/2000WO2000046246A1 Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease
08/10/2000WO2000046240A2 Polypeptides involved in immune response
1 ... 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 ... 1833